Nektar Therapeutics NKTR Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nektar Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nektar Therapeutics's accounts payable?
- Nektar Therapeutics (NKTR) reported accounts payable of $10.03M in Q1 2026.
- How has Nektar Therapeutics's accounts payable changed year-over-year?
- Nektar Therapeutics's accounts payable decreased by 43.8% year-over-year, from $17.83M to $10.03M.
- What is the long-term trend for Nektar Therapeutics's accounts payable?
- Over 5 years (2020 to 2025), Nektar Therapeutics's accounts payable has grown at a -13.4% compound annual growth rate (CAGR), from $22.14M to $10.77M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.